Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 2013. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding the GSK 401K plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory notification of a specific transaction rather than a financial performance report.
Material Changes
The filing details a revaluation of the cash element of the notional investment held within the GSK 401K plan, which is notionally held in GSK American Depositary Shares (ADSs). On August 30, 2013, at a price of $50.89 per ADS, the following increase in notional allocation occurred:
- Dr M Slaoui (Director/PDMR): No change in ADS allocation.
- Dr K Slaoui (Connected Person): Increase of 4 ADSs.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items beyond the specific transaction notification.
Key Facts for Investor Verification
- Transaction date: August 30, 2013.
- Notification date: September 4, 2013.
- ADS price at transaction: $50.89.
- Beneficiary of allocation increase: Dr K Slaoui (Connected Person).
- Regulatory basis: Disclosure and Transparency Rule 3.1.4R(1)(a) and (c).